Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality

Hypomethylating agents (HMA) with venetoclax is a new standard for older/unfit patients with acute myeloid leukemia (AML). However, it is unknown how HMA with venetoclax compare to intensive chemotherapy (IC) in patients who are ‘fit’ or ‘unfit’ for IC. We compared outcomes of older patients with ne...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Maiti, Abhishek, Qiao, Wei, Sasaki, Koji, Ravandi, Farhad, Kadia, Tapan M., Jabbour, Elias J., Daver, Naval G., Borthakur, Gautam, Garcia-Manero, Guillermo, Pierce, Sherry A., Montalbano, Kathryn S., Pemmaraju, Naveen, Naqvi, Kiran, Ohanian, Maro, Short, Nicholas J., Alvarado, Yesid, Takahashi, Koichi, Yilmaz, Musa, Jain, Nitin, Kornblau, Steven M., Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Issa, Ghayas C., Masarova, Lucia, Thompson, Philip A., Rausch, Caitlin R., Ning, Jing, Kantarjian, Hagop M., DiNardo, Courtney D., Konopleva, Marina Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8128145/
https://ncbi.nlm.nih.gov/pubmed/33264443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.26061
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky